Keyphrases
Chimeric Antigen Receptor T Cells (CAR-T)
100%
T Cells
35%
T Cell Depletion
29%
Chimeric Antigen Receptor T-cell Therapy
26%
Adoptive Cell Therapy
22%
Engineered T Cells
16%
T Cell Targeting
15%
B-cell Malignancies
15%
T Cell Activation
15%
CD19
15%
Cell Therapy
14%
Acute Lymphoblastic Leukemia
13%
Chimeric Antigen Receptor Therapy
13%
Clinical Trials
13%
Neuroblastoma
11%
Genome Editing
11%
Tumor
10%
4-1BB
9%
Resistance Mechanisms
8%
Co-stimulatory Domain
8%
CD22
8%
Adoptive Immunotherapy
8%
Xenograft Model
8%
Antigen-independent
8%
Highly Active
8%
Leukemia
8%
Cancer Immunotherapy
7%
Hematological Malignancies
7%
CART19
7%
Solid Tumors
7%
Autologous T Cell
7%
Culture Method
6%
Ovarian Cancer
6%
Chronic Lymphocytic Leukemia
6%
Pediatric Malignancy
6%
Non-Hodgkin Lymphoma
6%
Early Memories
5%
Memory Phenotype
5%
Hematopoietic Cell Transplantation
5%
CAR Therapy
5%
Clinical Application
5%
Immune Response
5%
Response Rate
5%
Medicine and Dentistry
T Cell
70%
Chimeric Antigen Receptor T-Cell
52%
Chimeric Antigen Receptor
33%
Cell Therapy
25%
Neoplasm
24%
Immunotherapy
21%
Chimeric Antigen Receptor T-Cell Immunotherapy
21%
Diseases
20%
Chimeric Antigen Receptor Immunotherapy
18%
Cancer
17%
Malignant Neoplasm
16%
B Cell
16%
Ganglioneuroblastoma
15%
Acute Lymphoblastic Leukemia
13%
Genome Editing
11%
Clinical Trial
10%
B-Cell Chronic Lymphocytic Leukemia
7%
B-Cell Lymphoma
7%
Solid Malignant Neoplasm
7%
Pediatrics
6%
Childhood Cancer
6%
Ovarian Cancer
6%
Cytotoxicity
6%
Hematologic Malignancy
6%
Leukemia
6%
Cell Transplantation
5%
Hematopoietic Cell
5%
Xenograft
5%
Immunocompetent Cell
5%
T Lymphocyte
5%
Immunology and Microbiology
T Cell
45%
Chimeric Antigen Receptor T-Cell
37%
Chimeric Antigen Receptor
36%
Immunotherapy
21%
CD19
11%
B Cell
9%
CD22
8%
Chimeric Antigen Receptor T-Cell Therapy
8%
Peptides
7%
Cell Function
7%
Cytotoxicity
6%
Antigen Specificity
5%